Lund, Sweden – August 14, 2019 – BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2019 on Thursday August 22 at 8.30 a.m. CEST, followed by an audiocast with teleconference at 11.00 a.m. CEST, hosted by Martin Welschof, CEO and members of the management team. The presentation will be held in English.

To participate, please call any of the following phone numbers from:

Sweden: +46 8 566 426 92
UK: +44 333 300 9272
US: +1 833 526 8383

Webcast: https://tv.streamfabriken.com/bioinvent-q2-2019

      
About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company’s lead program BI-1206, is currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent’s pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com